Next Article in Journal
Perspectives for 3D-Bioprinting in Modeling of Tumor Immune Evasion
Next Article in Special Issue
Receptor Tyrosine Kinases Amplified in Diffuse-Type Gastric Carcinoma: Potential Targeted Therapies and Novel Downstream Effectors
Previous Article in Journal
Feasibility and Acceptability of Bright IDEAS-Young Adults: A Problem-Solving Skills Training Intervention
Previous Article in Special Issue
Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors
 
 
Article
Peer-Review Record

The CBP/β-Catenin Antagonist, ICG-001, Inhibits Tumor Metastasis via Blocking of the miR-134/ITGB1 Axis-Mediated Cell Adhesion in Nasopharyngeal Carcinoma

Cancers 2022, 14(13), 3125; https://doi.org/10.3390/cancers14133125
by Luo Chen 1,†, Yiu Chun Chiang 1,†, Lai Sheung Chan 2, Wai Yin Chau 2, Maria Li Lung 3, Michael Kahn 4, Kwok Wai Lo 5,6, Nai Ki Mak 1 and Hong Lok Lung 2,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3:
Cancers 2022, 14(13), 3125; https://doi.org/10.3390/cancers14133125
Submission received: 13 June 2022 / Accepted: 17 June 2022 / Published: 25 June 2022
(This article belongs to the Special Issue A Deeper Dive into Signaling Pathways in Cancers)

Round 1

Reviewer 1 Report

The manuscript titled: “The CBP/β-catenin antagonist, ICG-001, inhibits tumor metastasis via blocking of the miR-134/ITGB1 axis-mediated cell adhesion in nasopharyngeal carcinoma” is well written with a unique scientific concept in the current cancer biology field. I have no comments on the current manuscript. I would suggest accepting the manuscript in its present form.

 

Reviewer 2 Report

Thanks for addressing the comments. 

Reviewer 3 Report

The authors have satisfactorily addressed all the concerns raised in the previous round. 

Back to TopTop